Hyloris’ Partner AFT Pharmaceuticals Signs Licensing Agreement with Aguettant for Maxigesic® IV in Eight European Markets
05 mars 2021 01h00 HE
|
Hyloris Pharmaceuticals
Hyloris’ Partner AFT Pharmaceuticals Signs Licensing Agreement with Aguettant for Maxigesic® IV in Eight European Markets Footprint across Europe now extended to a total of 20 EU member states ...
Hyloris appoints Dr. Dietmar Aichhorn as Chief Operating Officer
01 oct. 2020 07h00 HE
|
Hyloris Pharmaceuticals
Hyloris appoints Dr. Dietmar Aichhorn as Chief Operating Officer Liège, Belgium – 1 October 2020: Hyloris Pharmaceuticals SA, an innovative specialty pharmaceutical company focused on adding value to...
Hyloris announces approval of Maxigesic® IV in eight European countries
07 sept. 2020 04h37 HE
|
Hyloris Pharmaceuticals
Hyloris announces approval of Maxigesic® IV in eight European countries Commercialization of Hyloris’ second marketed product to start in early 2021 Liège, Belgium – 7 September 2020 – Hyloris...
Mid-Stabilisation Period Announcement
07 juil. 2020 12h31 HE
|
Hyloris Pharmaceuticals
Strictly Confidential NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY...
Hyloris Pharmaceuticals: Information on the total number of voting rights and shares – additional thresholds
30 juin 2020 03h00 HE
|
Hyloris Pharmaceuticals
RESS RELEASE Information on the total number of voting rights and shares – additional thresholds Liège (Belgium), 30 June 2020, 9h00 (CEST) – regulated information – In accordance with article 15 of...
Hyloris Pharmaceuticals Announces Coverage of the Maximum Offering Size, including Increase Option and Over-Allotment, at the Midpoint of the Price Range of its Initial Public Offering on Euronext Brussels
19 juin 2020 12h10 HE
|
Hyloris Pharmaceuticals
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SWITZERLAND, ISRAEL, JAPAN OR SOUTH AFRICA This announcement does not constitute an...
Hyloris Pharmaceuticals Announces the Coverage of the Base Offering Throughout the Price Range of its Initial Public Offering on Euronext Brussels
18 juin 2020 11h03 HE
|
Hyloris Pharmaceuticals
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SWITZERLAND, ISRAEL, JAPAN OR SOUTH AFRICA This announcement does not constitute an offer to...